Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Henderson Morley has signed a material transfer and collaborative research agreement with the Australian Centre for Vaccine Development, part of the Queensland Institute of Medical Research.
Subscribe to our email newsletter
The collaborative research agreement is to undertake the development of a vaccine targeted at preventing cytomegalovirus (CMV) disease the most important preventable infectious disease of unborn children in the developed world.
The collaboration will use a combination of technologies from Henderson Morley and Australian Centre for Vaccine Development (ACVD). Each party shall bear its own development costs, and any new intellectual property arising out of this collaboration shall vest jointly in Henderson Morley and ACVD.
The collaborative project will be using a CMV polyepitope antigen developed by the team at ACVD, incorporated into the PREPS and L-particles delivery vector, to produce a new vaccine candidate targeted at numerous strains of CMV.